0001193125-23-303015.txt : 20231226 0001193125-23-303015.hdr.sgml : 20231226 20231226161026 ACCESSION NUMBER: 0001193125-23-303015 CONFORMED SUBMISSION TYPE: 25 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20231226 DATE AS OF CHANGE: 20231226 EFFECTIVENESS DATE: 20231226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001723128 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38485 FILM NUMBER: 231513437 BUSINESS ADDRESS: BUSINESS PHONE: (908) 947-3120 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Holdings, Inc. DATE OF NAME CHANGE: 20171117 25 1 d618150d25.htm 25 25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

FORM 25

 

 

NOTIFICATION OF REMOVAL FROM LISTING

AND/OR REGISTRATION UNDER SECTION 12(b)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-38485

 

 

Amneal Pharmaceuticals, Inc., New York Stock Exchange

(Exact name of Issuer as specified in its charter, and name of Exchange

where security is listed and/or registered)

 

 

400 Crossing Blvd

Bridgewater, NJ, 08807

(908) 947-3120

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Class A Common Stock, par value $0.01 per share

(Description of class of securities)

 

 

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

 

☐

17 CFR 240.12d2-2(a)(1)

 

☐

17 CFR 240.12d2-2(a)(2)

 

☐

17 CFR 240.12d2-2(a)(3)

 

☐

17 CFR 240.12d2-2(a)(4)

 

☐

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.(1)

 

☒

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Amneal Pharmaceuticals, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

 

December 26, 2023

      

/s/ Anastasios Konidaris

     

Executive Vice President and

Chief Financial Officer

Date       Name: Anastasios Konidaris      Title

 

(1)

Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions